Back to Search
Start Over
Airsupra demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
- Source :
- European Union News. October 9, 2024
- Publication Year :
- 2024
-
Abstract
- Cambridge, United Kingdom: AstraZeneca has issued the following press release: Positive high-level results from the BATURA Phase IIIb trial showed AstraZeneca's Airsupra (albuterol/budesonide) met the primary endpoint, demonstrating a statistically [...]
- Subjects :
- AstraZeneca PLC -- Product development
Airsupra (Medication) -- Product development
Diseases
Care and treatment
Product development
Clinical trials
Type 2 diabetes -- Care and treatment
Glucocorticoids
Pharmaceutical industry -- Product development
Asthma -- Care and treatment
Corticosteroids
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- European Union News
- Publication Type :
- News
- Accession number :
- edsgcl.811777300